Literature DB >> 21245656

Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity.

Ellen Murphy1, Shuo L Lin, Lorna Nunez, Lubomira Andrew, Pamela S Fink, Deborah A Dilts, Susan K Hoiseth, Kathrin U Jansen, Annaliesa S Anderson.   

Abstract

Clumping factors A (ClfA) and B (ClfB) are Staphylococcus aureus virulence proteins that are displayed on the cell surface of the organism and have potential as vaccine antigens for the prevention of S. aureus disease. Here we evaluate the phylogeny of S. aureus in the context of antigenic variation of these two surface proteins. ClfA and ClfB gene sequences, along with epidemiological markers (MLST, spa and capsule genotype) were obtained for 224 S. aureus isolates including both historical strains and a collection representative of current MRSA isolates from the United States. Variation within ClfA and ClfB was consistent with the established population biology of S. aureus, namely, that S. aureus strains belong to a relatively small number of clonal lineages, with evolution proceeding mainly by mutation and with little to no recombination between clades. Thus most variation in ClfA and ClfB occurs between but not within lineages, and particular groups of ClfA and ClfB variants are closely linked. This has important implications for vaccine development and assessment as it suggests that a relatively small survey of strains will be representative of the total population variation, whereas for species that evolve mainly by recombination, such as Neisseria meningitidis, analysis of a much larger number of strains is needed to accomplish the same purpose. Our study also revealed evidence for the de-evolution of ClfB and therefore its reduced suitability as a target for vaccine development compared to ClfA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245656     DOI: 10.4161/hv.7.0.14562

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  23 in total

1.  Immunogenicity analysis of Staphylococcus aureus clumping factor A genetic variants.

Authors:  Rebecca A Brady; Christopher P Mocca; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2013-06-26

2.  Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis.

Authors:  Santiago M Lattar; Mariángeles Noto Llana; Philippe Denoël; Sophie Germain; Fernanda R Buzzola; Jean C Lee; Daniel O Sordelli
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

3.  A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure.

Authors:  Julio Hawkins; Srinivas Kodali; Yury V Matsuka; Lisa K McNeil; Terri Mininni; Ingrid L Scully; John H Vernachio; Elena Severina; Douglas Girgenti; Kathrin U Jansen; Annaliesa S Anderson; Robert G K Donald
Journal:  Clin Vaccine Immunol       Date:  2012-08-15

4.  Nasopharyngeal colonization elicits antibody responses to staphylococcal and pneumococcal proteins that are not associated with a reduced risk of subsequent carriage.

Authors:  Sabine M P J Prevaes; Willem J B van Wamel; Corné P de Vogel; Reinier H Veenhoven; Elske J M van Gils; Alex van Belkum; Elisabeth A M Sanders; Debby Bogaert
Journal:  Infect Immun       Date:  2012-03-26       Impact factor: 3.441

5.  Safety of Staphylococcus aureus four-antigen and three-antigen vaccines in healthy adults: A meta-analysis of randomized controlled trials.

Authors:  Xiaoqun Xu; Houyong Zhu; Huoyang Lv
Journal:  Hum Vaccin Immunother       Date:  2017-12-06       Impact factor: 3.452

6.  Clumping Factor B Promotes Adherence of Staphylococcus aureus to Corneocytes in Atopic Dermatitis.

Authors:  Orla M Fleury; Maeve A McAleer; Cécile Feuillie; Cécile Formosa-Dague; Emily Sansevere; Désirée E Bennett; Aisling M Towell; W H Irwin McLean; Sanja Kezic; D Ashley Robinson; Padraic G Fallon; Timothy J Foster; Yves F Dufrêne; Alan D Irvine; Joan A Geoghegan
Journal:  Infect Immun       Date:  2017-05-23       Impact factor: 3.441

7.  Structural and biochemical characterization of Staphylococcus aureus clumping factor B/ligand interactions.

Authors:  Vannakambadi K Ganesh; E Magda Barbu; Champion C S Deivanayagam; Binh Le; Analiesa S Anderson; Yury V Matsuka; Shuo L Lin; Timothy J Foster; Sthanam V L Narayana; Magnus Höök
Journal:  J Biol Chem       Date:  2011-05-03       Impact factor: 5.157

8.  Allantodapsone is a Pan-Inhibitor of Staphylococcus aureus Adhesion to Fibrinogen, Loricrin, and Cytokeratin 10.

Authors:  Filippo Prencipe; Aishah Alsibaee; Zainab Khaddem; Padraig Norton; Aisling M Towell; Afnan F M Ali; Gerard Reid; Orla M Fleury; Timothy J Foster; Joan A Geoghegan; Isabel Rozas; Marian P Brennan
Journal:  Microbiol Spectr       Date:  2022-06-01

9.  Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis.

Authors:  Annaliesa S Anderson; Ingrid L Scully; Yekaterina Timofeyeva; Ellen Murphy; Lisa K McNeil; Terri Mininni; Lorna Nuñez; Marjolaine Carriere; Christine Singer; Deborah A Dilts; Kathrin U Jansen
Journal:  J Infect Dis       Date:  2012-04-02       Impact factor: 5.226

Review 10.  Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors.

Authors:  Annaliesa S Anderson; Alita A Miller; Robert G K Donald; Ingrid L Scully; Jasdeep S Nanra; David Cooper; Kathrin U Jansen
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.